For trailing twelve months, EPS value for the stock is $-0.05. In addition, it engages in developing and commercializing hGH-CTP, a recombinant human growth hormone product that is in Phase III; developing Factor VIIa drug for hemophilia that is in Phase IIa, an NK-1 compound, and drugs for treating asthma and chronic obstructive pulmonary disease; developing and producing specialty active pharmaceutical ingredients; discovery of drugs for the treatment of cancer, heart disease, metabolic disorders, and a range of genetic anomalies.
On Tuesday, April 11th, Phillip Md Et Al Frost purchased 18,000 shares of Opko Health stock. The stock was bought at an average cost of $7.49 per share, with a total value of $134,820.00. The stock was acquired at an average cost of $8.02 per share, with a total value of $85,012.00.
On Friday, April 7th, Phillip Md Et Al Frost purchased 28,000 shares of Opko Health stock. The stock was bought at an average cost of $7.58 per share, with a total value of $212,240.00.
On Thursday, April 6th, Phillip Md Et Al Frost acquired 28,600 shares of Opko Health stock. The stock dropped -6.32% beyond one week and declined -12.44% during previous one month session.
On Wednesday, April 5th, Phillip Md Et Al Frost acquired 44,500 shares of Opko Health stock. The stock was acquired at an average price of $7.69 per share, with a total value of $342,205.00.More news: NASA New Discoveries: Saturn, Jupiter Moons May Be Able To Support Life
On Tuesday, April 4th, Phillip Md Et Al Frost acquired 7,400 shares of Opko Health stock. The shares were bought at an average price of $7.60 per share, with a total value of $250,800.00. Opko Health Inc. has a 12 month low of $7.13 and a 12 month high of $12.15. (OPK) are trading -41.48% downward from the 52-week high mark and -0.28% below from the fifty two-week low mark. Overall, 5.94 Million shares exchanged hands versus its average trading volume of 4.39 Million shares. The company has market cap of $4.23 billion.
Over the past 50 days, Opko Health, Inc. stock's -15.58% off of the high and 5.91% removed from the low. The biotechnology company reported ($0.04) earnings per share for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.04).
Currently, EPS of Opko Health, Inc. The company's revenue was down.3% on a year-over-year basis. Opko Health, Inc. (OPK) now trades with a market capitalization of $4.26 Billion.
TRADEMARK VIOLATION WARNING: "Insider Buying: Opko Health Inc".
Based on their most recently released notes to investors, 2 analysts have a rating of "buy", 3 analysts "outperform", 1 analysts "hold", 0 analysts "underperform" and 0 analysts "sell". If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of US & global trademark & copyright legislation. The correct version of this article can be read at https://www.thecerbatgem.com/2017/04/20/opko-health-inc-opk-ceo-phillip-md-et-al-frost-purchases-7400-shares-of-stock-updated.html.More news: Will Smith death: Man who killed National Football League star sentenced to 25 years
Want to see what other hedge funds are holding OPK? National Planning Corp increased its position in Opko Health by 1.2% in the fourth quarter. Exencial Wealth Advisors LLC now owns 22,000 shares of the company's stock worth $205,000 after buying an additional 2,000 shares during the last quarter. Whalerock Point Partners LLC purchased a new position in Opko Health during the third quarter worth about $2,100,000. Finally, Russell Investments Group Ltd. bought a new stake in shares of Opko Health during the fourth quarter worth $648,000. Perhaps, that suggests something about why 6.83% of the outstanding share supply is held by institutional investors. (OPK) is $15.92/share according to the consensus of analysts working on the stock, with an expected EPS of $-0.03/share for the current quarter. The analysts estimated sales for the higher end at 353.4 million and lower end at 310.4 million while the year ago reported sale was 350.3 million.
01/03/2017 - Opko Health Inc had its "buy" rating reiterated by analysts at Laidlaw. Zacks Investment Research cut Opko Health from a "hold" rating to a "sell" rating in a report on Wednesday, January 18th.
03/03/2017 - Opko Health Inc had its " rating reiterated by analysts at Standpoint Research. One analyst has rated the stock with a sell rating, three have given a hold rating and five have issued a buy rating to the company.
Currently, the market capitalization of Opko Health, Inc. The company's Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases.More news: Corsair Hydro GFX GTX 1080 Ti smokes the competition
- United States considers shooting down N.Korea missile tests
- UC Berkeley flip-flops on Ann Coulter, proposes May date
- Youth detained for post against Andhra CM
- Rams hosting Colts in fall season opener
- Canada's telecom regulator rules online data be treated equally
- Ultra-mobile Windows 10 PCs built with smartphone processors coming this year
- Monaco's Mbappe sets Champions League records against Borussia Dortmund
- Marine Le Pen loses ground to Emmanuel Macron in French election race
- Iran not pulling weight on 2015 nuclear deal
- U.K. Lawmakers Vote in Favor of Early Election on June 8